The Authorised Prescriber Pathway for Psilocybin

Psilocybin is still a prohibited substance , start there

Forty-three years after the United Nations Convention on Psychotropic Substances classified psilocybin as a Schedule I drug, Australia made a quiet but significant regulatory move. On 1 July 2023, the Therapeutic Goods Administration rescheduled psilocybin , under very specific conditions , from Schedule 9 (prohibited substance) to Schedule 8 (controlled drug) for authorised use. The headlines ran warm. The actual legal picture is more careful than that.

Let me be plain about what didn't change. Outside the narrow pathway described below, psilocybin remains a Schedule 9 prohibited substance under Australia's Poisons Standard. Possession, use, production, or supply outside the authorised framework is a criminal offence. The penalties vary by state and territory, but the illegality does not.

What did change is that a specific class of medical practitioners can now, under defined conditions, prescribe psilocybin to specific patients. Understanding that pathway; what it requires, who it covers, and where its boundaries sit, is what this piece is about.

The Authorised Prescriber framework: a brief anatomy

The Authorised Prescriber (AP) scheme is one of two access pathways in Australia for unapproved therapeutic goods, the other being the Special Access Scheme (SAS). Neither pathway is new; both existed long before the 2023 psilocybin decision. What changed is that psilocybin became eligible to move through them.

Under the AP scheme, a medical practitioner applies to the TGA for authorisation to prescribe a specific unapproved or controlled substance to a defined class of patients. The application requires approval from a Human Research Ethics Committee (HREC) or, in some cases, endorsement from an approved specialist college. Once authorised, the prescriber must report prescribing numbers to the TGA every six months and notify the TGA if they stop prescribing.

For psilocybin specifically, the 2023 rescheduling decision stipulates that it may only be prescribed by an Authorised Prescriber for one indication class: treatment-resistant depression. The prescribing must occur in a controlled clinical setting. The substance sits at Schedule 8 for this purpose; the same schedule as morphine and oxycodone, which means the full architecture of controlled-drug oversight applies: prescriber records, dispensing records, state and territory controlled-drug authorities, and storage requirements.

This is not a community access pathway. It is not over-the-counter. It is not something a GP can simply decide to prescribe.

What the chemistry actually involves

Psilocybin is a naturally occurring tryptamine, found in certain fungal species. Once ingested, it is rapidly dephosphorylated to psilocin, which acts primarily as a partial agonist at serotonin receptors, most notably the 5-HT2A receptor, broadly expressed in cortical regions. The pharmacokinetics of psilocin are relatively well characterised: oral bioavailability is moderate, hepatic metabolism is significant (involving first-pass metabolism), and the subjective effects in clinical studies typically span four to six hours.

I'll admit I spent more time than I should have tracking down the early metabolic studies on this; they're scattered across several decades and not always easy to reconcile. The short version is: psilocin's primary receptor activity differs substantially from the cannabinoid system's pathways (the endocannabinoid system operates via an entirely separate receptor class), but the regulatory complexity involved in accessing either class of compound in Australia is, if anything, greater for psychedelics.

Imaging studies, primarily from Johns Hopkins and Imperial College London, have reported altered functional connectivity in the default mode network during psilocybin sessions. These findings are published, peer-reviewed, and actively debated in terms of what they mean mechanistically. What they don't yet constitute is a proven, approved therapeutic mechanism. The TGA's 2023 decision noted that the evidence base, whilst showing promise, remains limited and that the rescheduling was conditional rather than an endorsement of established efficacy.

What the clinical research actually shows, and what it doesn't

The most widely cited clinical work includes the COMPASS Pathways Phase IIb trial (published in New England Journal of Medicine, 2022) and several studies out of Johns Hopkins. These report outcomes under controlled conditions with trained facilitators, structured screening, and specific patient populations. I'd encourage anyone reading this to look at those papers directly rather than at the press releases, the effect sizes, the dropout rates, and the study design limitations deserve attention.

Honestly, some of the popular science coverage of psilocybin research has been enthusiastic to a fault. The published trials generally involve small-to-medium sample sizes, short follow-up periods, and heterogeneous methodologies. The 2022 NEJM trial found mixed results across its three dosing cohorts. That nuance tends to get lost.

None of this means the research is unimportant. It means the research is ongoing, and the AP framework in Australia reflects that; it's a controlled pathway, not an open door.

The screening and setting requirements

One aspect of the AP framework that doesn't always make it into public discussion is the clinical infrastructure it assumes. The TGA's authorised prescriber framework for psilocybin requires that administration occur in a clinical setting with psychological support, what the research literature calls "psychedelic-assisted therapy" involves preparatory sessions, the dosing session itself (conducted with trained support persons present), and integration sessions afterwards.

This is resource-intensive. It requires practitioners trained in both the clinical and psychological dimensions of the session, appropriate physical facilities, and a willingness to navigate the state/territory controlled-drug authority requirements that sit on top of the federal TGA framework. Perth has seen some early interest in establishing compliant clinical settings, but as of mid-2025, the number of active Authorised Prescribers for psilocybin nationally remains very small relative to the patient populations who might theoretically qualify.

The upshot is that even for patients who technically meet the criteria for treatment-resistant depression, access through this pathway is far from straightforward. The legal architecture exists. The clinical infrastructure is still being built.

What the rescheduling does not permit

A few things bear stating clearly because the 2023 decision generated some genuine confusion.

The rescheduling does not decriminalise personal possession. It does not create a regulated recreational market. It does not permit ceremonies, retreats, or community-based sessions to operate legally under this framework, those remain Schedule 9 territory and therefore criminal. The AP pathway is strictly clinical, strictly prescriber-led, and strictly limited to treatment-resistant depression as the approved indication class.

MDMA, which many people associate with the same wave of psychedelic research, was also rescheduled at the same time to Schedule 8 for post-traumatic stress disorder under the AP framework. It faces the same infrastructure and access constraints.

The Australian Drug Foundation's published information on psilocybin continues to note the serious legal risks of use outside medical supervision, and that the drug carries real psychological risks; including acute psychological distress and potential triggering of latent psychiatric conditions, that the clinical framework exists precisely to screen for and manage.

Where the regulatory picture stands now

The TGA publishes updated information on the Authorised Prescriber scheme at tga.gov.au, including guidance documents for practitioners seeking to apply. Any practitioner considering the pathway needs to engage with those documents and with their relevant HREC, this is not a process that can be summarised in a paragraph.

For researchers, the other relevant pathway is clinical trials registered through the Australian New Zealand Clinical Trials Registry (ANZCTR), which can allow psilocybin use under an entirely separate regulatory framework governed by the TGA's clinical trial provisions.

What we're watching; and I use "watching" deliberately, not as a prediction, is whether the clinical infrastructure catches up to the regulatory permission that now formally exists. That's a question for the next few years of data, not something already settled.

Sources

• Scheduling Delegate's Final Decisions: Psilocybin and MDMA (February 2023), Therapeutic Goods Administration (TGA)
• Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (2022); New England Journal of Medicine
• Magic Mushrooms (Psilocybin) Drug Facts, Australian Drug Foundation (ADF)
• Authorised Prescriber Scheme, Therapeutic Goods Administration (TGA)

, Daniel Okoro, Psychedelic science & law writer